PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
Hair follicles can be dormant and potentially revived with treatments like finasteride and minoxidil, but irreversible loss occurs if certain structures are destroyed. Early intervention is more effective, and additional methods like microneedling may help.
HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.
The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly credits a person for the potential success of a treatment called GT20029.
Hair loss is linked to DHT, with treatments like finasteride and minoxidil being common but not definitive. Economic interests influence research, and there is potential for new treatments like PP405 and RU58841.
The conversation is about using Maxogen-X, a topical solution containing minoxidil, finasteride, tretinoin, and azelaic acid, for hair loss treatment. Users discuss their experiences, including initial shedding and the hope for thicker hair, while sharing progress updates.
Users discussed using GHK-Cu and AHK-Cu peptides with microneedling for hair loss, noting some small changes after 7-8 weeks. They mentioned continued shedding but no widening of the part.
Han Bio plans to start Phase 1 clinical trials for a hair growth treatment in 2027 after successful results in mice. Many users express skepticism about the effectiveness of treatments that work on mice but not on humans, and discuss existing treatments like finasteride and minoxidil.
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
User had minor hair transplant in 2020, used Fin since 2008, Min since 2014, and added microneedling in 2022. Routine was irregular with no severe effects.
User starts Nuclear Stack treatment for hair loss, including Dutasteride, Minoxidil, RU58841, Derminator 2, and supplements. Seeks advice on storing and dosing RU58841.
The conversation discusses using finasteride or dutasteride to reduce DHT, CosmeRNA to target androgen receptors, and Minoxidil as a vasodilator for hair growth. The regimen aims to maintain hair by addressing DHT-AR ratio and continuous Minoxidil use.
GHK-Cu and AHK-Cu peptides show limited success for hair loss, with skepticism about their effectiveness and concerns about misleading claims. Users report better results when combined with treatments like finasteride, dutasteride, minoxidil, and other methods.
Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.
Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.
People on testosterone replacement therapy (TRT) with aggressive androgenetic alopecia (AGA) discuss using Dutasteride or Finasteride, sometimes combined with topical treatments like RU58841 or CB-03-01 (Breezula), to prevent hair loss. Concerns about side effects and costs of certain treatments are mentioned, with one individual sharing their experience of slowed hair loss using Finasteride alone.
The conversation discusses the use of AlphaInfuse, a micro-infusion system with Panax ginseng and Eclipta prostrata extracts, for hair growth and its comparison to Minoxidil. The original poster seeks personal experiences and evidence of its effectiveness.
The conversation is about someone considering a hair transplant due to ineffective hair loss treatments, with suggestions ranging from trying a hairpiece to continuing with medications like finasteride and minoxidil, and waiting for new treatments. Some advise against a transplant due to the extent of hair loss and the cost, while others share different views on the effectiveness of transplants and non-surgical options.
The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.
A 22-year-old is experiencing aggressive hair loss despite using minoxidil and finasteride and is considering a hair transplant but lacks funds. The discussion includes advice on treatments like dutasteride, microneedling, and lifestyle changes, with mixed opinions on the timing and effectiveness of a transplant at a young age.
Bee venom at 0.001% concentration was more effective than 2% minoxidil in promoting hair growth in mice, possibly due to increased growth factors and reduced inflammation. Caution is advised due to potential allergic reactions and the reliance on animal data.
Liver problems may reduce the effectiveness of oral minoxidil due to impaired SULT1A1 enzyme activity, which is crucial for converting minoxidil to its active form. This reduction in enzyme function can significantly decrease the drug's effectiveness in promoting hair growth.
The user has been using Minoxidil, finasteride, and a dermaroller for a year with little effect on hair loss. They are considering a hair transplant and are questioning the number of grafts needed and the feasibility of transplanting onto a partially bald scalp.
PP405 may revive dormant hair follicles, and DHT blockers like finasteride or dutasteride could maintain new hair. Combining PP405 with minoxidil might be optimal, but long-term effects and continuous use are uncertain.
The conversation discusses the tension theory as a cause of male pattern baldness (MPB), suggesting that scalp tension and reduced subcutaneous fat layer contribute to hair loss. Treatments mentioned include Minoxidil, finasteride, microneedling, scalp massages, and Botox.
PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.
HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.
A user shared their pre-finasteride lab results, including DHT, estradiol, testosterone, SHBG, prolactin, FSH, and LH levels. Another user responded, cautioning against making unsupported claims about side effects and recovery.